Literature DB >> 23379954

Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.

Takashi Karashima1, Hideo Fukuhara, Kenji Tamura, Shingo Ashida, Masayuki Kamada, Keiji Inoue, Takahiro Taguchi, Naoto Kuroda, Taro Shuin.   

Abstract

OBJECTIVES: To investigate the potential mechanism of development of resistance to tyrosine kinase inhibitor in renal cell carcinoma.
METHODS: A primary culture of renal cell carcinoma cells (KMRM-S2) was established from an advanced renal cell carcinoma patient with cutaneous metastasis, who had not responded to sorafenib. A total of 84 human angiogenesis-related genes were compared between cutaneous metastasis and the primary tumor by real time polymerase chain reaction. Spectral karyotyping and cell proliferation assay were carried out to determine the biological features of the cells.
RESULTS: Primary tumor was histopathologically diagnosed as high-grade clear cell carcinoma with sarcomatoid change and rhabdoid features. The cutaneous metastasis also consisted of sarcomatoid components. Expression levels of many angiogenesis-related genes in the cutaneous metastasis were relatively higher than those of primary tumor. Chromosomal analysis of the KMRM-S2 showed cytogenetic abnormalities with hypertriploidy and translocation. In vitro proliferation assay showed the relatively higher resistance of KMRM-S2 against sorafenib.
CONCLUSIONS: The sarcomatoid change and rhabdoid features of renal cell carcinoma with cytogenetic hyperploidy might be associated with elevated expression of angiogenesis-related genes, which leads to resistance against tyrosine kinase inhibitor. The present study might contribute to discovering novel therapeutic targets for the treatment of patients with advanced renal cell carcinoma resistant to tyrosine kinase inhibitor.
© 2013 The Japanese Urological Association.

Entities:  

Keywords:  angiogenesis-related genes; renal cell carcinoma; resistance; tyrosine-kinase inhibitor

Mesh:

Substances:

Year:  2013        PMID: 23379954     DOI: 10.1111/iju.12084

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

Review 1.  Advances in Renal Cell Carcinoma Drug Resistance Models.

Authors:  Yien Xiang; Ge Zheng; Jianfeng Zhong; Jiyao Sheng; Hanjiao Qin
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

2.  Expression of angiogenic factors is increased in metastasised renal cell carcinomas.

Authors:  Mahmoud Abbas; Johannes Salem; Angelika Stucki-Koch; Mareike Rickmann; Viktor Grünwald; Thomas Herrmann; Danny Jonigk; Hans Kreipe; Kais Hussein
Journal:  Virchows Arch       Date:  2014-01-14       Impact factor: 4.064

3.  Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC).

Authors:  Zofia F Bielecka; Anna M Czarnecka; Wojciech Solarek; Anna Kornakiewicz; Cezary Szczylik
Journal:  Curr Signal Transduct Ther       Date:  2014-12

4.  The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.

Authors:  Helena Polena; Julie Creuzet; Maeva Dufies; Adama Sidibé; Abir Khalil-Mgharbel; Aude Salomon; Alban Deroux; Jean-Louis Quesada; Caroline Roelants; Odile Filhol; Claude Cochet; Ellen Blanc; Céline Ferlay-Segura; Delphine Borchiellini; Jean-Marc Ferrero; Bernard Escudier; Sylvie Négrier; Gilles Pages; Isabelle Vilgrain
Journal:  Br J Cancer       Date:  2018-03-22       Impact factor: 7.640

5.  Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma.

Authors:  Thea Reinkens; Amelie Stalke; Nicole Huge; Beate Vajen; Marlies Eilers; Vera Schäffer; Oliver Dittrich-Breiholz; Brigitte Schlegelberger; Thomas Illig; Britta Skawran
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

6.  Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.

Authors:  Cristina Quintavalle; Sravanth Kumar Hindupur; Luca Quagliata; Pierlorenzo Pallante; Cecilia Nigro; Gerolama Condorelli; Jesper Bøje Andersen; Katrin Elisabeth Tagscherer; Wilfried Roth; Francesco Beguinot; Markus Hermann Heim; Charlotte Kiu Yan Ng; Salvatore Piscuoglio; Matthias Sebastian Matter
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.